showed that the frequency of mutations in genes outside of JAK2 was higher in patients failing to achieve a complete molecular remission (CMR) (56%) versus those achieving CMR (30%), although this difference did not reach statistical significance.
← all excerpts
Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
1
—
—